BioStock: Ultimovacs receives dual FDA Fast Track for UV1

Ultimovacs’ mission to develop a cancer vaccine just received a significant boost. The FDA has granted dual Fast Track designation for the company’s candidate UV1 as an add-on therapy to checkpoint inhibitors in advanced malignant melanoma patients. The designation potentially provides expedited review of UV1 for approval.

Read the article at biostock.se:

https://www.biostock.se/en/2021/10/ultimovacs-receives-dual-fda-fast-track-for-uv1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se